Prochlorperazine Maleate Intramuscular (IM) and intravenous (IV) injection manufacturers & suppliers

Prochlorperazine Maleate Intramuscular (Im) And Intravenous (Iv) Injection

Form: Intramuscular (IM) and intravenous (IV) injection

Strength: 5 mg/mL (1 mL ampoules)

Reference Brands: US: Compazine®, Procomp®; EU: Stemetil®, Buccastem®

Category: Antipsychotropic Drugs

Prochlorperazine Maleate is a versatile phenothiazine-class medication used to manage nausea, vomiting, vertigo, schizophrenia, and migraines. Widely marketed in the US as Compazine® and in the EU as Stemetil® and Buccastem®, it is available in multiple dosage forms including oral tablets (5 mg, 10 mg), buccal tablets (3 mg), rectal suppositories (25 mg), and injections (5 mg/mL). Its broad therapeutic use makes it a valuable molecule in both hospital and retail supply chains. Source Prochlorperazine Maleate APIs and finished dosage forms directly from verified manufacturers and suppliers at Pharmatradz.com—your global B2B pharma network.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details
Zuclopenthixol Short-Acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details
Zuclopenthixol Tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.